Calidi Biotherapeutics, Inc. (CLDI) News
Follow Calidi Biotherapeutics, Inc. (CLDI) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Calidi Biotherapeutics Received Notice of Noncompliance
On September 21, 2026, the company received a notice from NYSE American that it is not in compliance with Section 1003(a)(ii) due to stockholders' equity of $3.1 million versus the $4.0 million requirement and losses in
NEWS | Sep 25, 2026, 09:35 PM UTC
L
Calidi Biotherapeutics, Inc. (CLDI) Gets NYSE American Equity Deficiency Notice
Calidi Biotherapeutics received an NYSE American notice for non-compliance with stockholders’ equity requirements and must submit a plan by Oct. 21, 2026 to regain compliance by Mar. 21, 2028, or face potential delisting
NEWS | Sep 25, 2026, 09:02 PM UTC
L
Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency
SAN DIEGO, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announ
NEWS | Sep 25, 2026, 09:02 PM UTC
M
Calidi Biotherapeutics raises $1.2M via registered direct offering
Calidi Biotherapeutics sold 1,025,640 common shares at $1.17 per share, generating about $1.2 million in gross proceeds. The offering closed September 21, 2026.
EQUITY | Sep 22, 2026, 09:03 PM UTC
L
CLDI - Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
CLDI - Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
NEWS | Sep 17, 2026, 01:11 PM UTC
L
Calidi Biotherapeutics to participate in H.C. Wainwright 28th conference
Calidi Biotherapeutics Inc. (NYSE American: CLDI) said it will participate in the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 08, 2026, 12:07 PM UTC
L
CLDI - Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
CLDI - Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
EQUITY | Sep 08, 2026, 12:00 PM UTC
L
Calidi Biotherapeutics reports Q2 2026 financial results
Calidi Biotherapeutics (CLDI) reports its second quarter 2026 financial results and recent business highlights.
EARNINGS | Aug 13, 2026, 08:30 PM UTC
L
CSAI, NEXR, CLDI, OFAL Split
CSAI, NEXR, CLDI, OFAL undergo reverse stock splits
EQUITY | Jul 30, 2026, 09:19 PM UTC
M
CSAI, NEXR, CLDI, OFAL Split
Stock splits for CSAI, NEXR, CLDI, OFAL
EQUITY | Jul 30, 2026, 02:56 PM UTC
L
CLDI - Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Asso
CLDI - Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference
EQUITY | Jul 27, 2026, 12:00 PM UTC
H
Why Crown Holdings Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Crown Holdings Inc (NYSE: CCK ) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results and raised its FY26 adjusted EPS guidance above estimates. Cro
EARNINGS | Jul 21, 2026, 09:11 AM UTC
M
CLDI Presents T-Cell Data
Calidi Biotherapeutics Presents Data On Its Approach Of Simultaneously Activating T-cells While Inducing Expression Of T-Cell Engagers Specifically In Situ In Tumor Microenvironment
EQUITY | Jun 24, 2026, 12:07 PM UTC
M
CLDI Presents CLD-501 Data
Calidi Biotherapeutics presents new data on CLD-501, its in situ T-cell engager candidate targeting TROP-2
EQUITY | Jun 24, 2026, 12:00 PM UTC
L
CLDI Appoints Corsee Sanders
Calidi Biotherapeutics appoints Corsee Sanders, Ph.D., to its Board of Directors, bringing over three decades of biopharmaceutical development experience
EQUITY | Jun 23, 2026, 12:01 PM UTC